- Sep 24, 2002
- 4,466
- 0
- 0
http://www.msnbc.msn.com/id/58...p;&PS=70102&SU
"The most startling fact about 2002 is that the combined profits for the 10 drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion). "
basically universities are funding a majority of research/pre-research for drug companies (essentially subsidizing them greatly). so why shouldn't americans enjoy the benefits the most instead of having to pay the most. to the point where we have to ship drugs to canada only to buy them back. <insert canadian currency joke here>
another fact to throw in is that most drug co's spend more on marketing than actual drug development
so i guess that explains why has health premiums risen 50% in the last 4 years driving double-digit recession proof growth for drug co's, not to mention college tuition risising several times inflation each year even though logically they'd be lower if the drug co's were fairly sharing that drug research bling bling
glad they got the double tax breaks they deserve.
"The most startling fact about 2002 is that the combined profits for the 10 drug companies in the Fortune 500 ($35.9 billion) were more than the profits for all the other 490 businesses put together ($33.7 billion). "
basically universities are funding a majority of research/pre-research for drug companies (essentially subsidizing them greatly). so why shouldn't americans enjoy the benefits the most instead of having to pay the most. to the point where we have to ship drugs to canada only to buy them back. <insert canadian currency joke here>
another fact to throw in is that most drug co's spend more on marketing than actual drug development
so i guess that explains why has health premiums risen 50% in the last 4 years driving double-digit recession proof growth for drug co's, not to mention college tuition risising several times inflation each year even though logically they'd be lower if the drug co's were fairly sharing that drug research bling bling
the former chairman and CEO of Bristol-Myers Squibb, Charles A. Heimbold Jr., made $74,890,918 in 2001, not counting his $76,095,611 worth of unexercised stock options. The chairman of Wyeth made $40,521,011, exclusive of his $40,629,459 in stock options
glad they got the double tax breaks they deserve.